Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies

2011 ◽  
Vol 26 (13) ◽  
pp. 2422-2427 ◽  
Author(s):  
Peggy Reiner ◽  
Damien Galanaud ◽  
Gaëlle Leroux ◽  
Marie Vidailhet ◽  
Julien Haroche ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome

Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Simone Fargetti ◽  
Michelle R. Ugolini-Lopes ◽  
Sandra G. Pasoto ◽  
Luciana P. C. Seguro ◽  
Samuel K. Shinjo ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Peripheral Neuropathy ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Short And Long Term

Characteristics and Long-Term Outcome of 15 Episodes of Systemic Lupus Erythematosus-Associated Hemophagocytic Syndrome

Medicine ◽  
2006 ◽  
Vol 85 (3) ◽  
pp. 169-182 ◽  
Author(s):  
Olivier Lambotte ◽  
Mehdi Khellaf ◽  
Hicham Harmouche ◽  
Brigitte Bader-Meunier ◽  
Véronique Manceron ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Hemophagocytic Syndrome ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome

LONG-TERM OUTCOME OF KIDNEY TRANSPLANTATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

1998 ◽  
Vol 66 (8) ◽  
pp. 1000-1003 ◽  
Author(s):  
Philippe Grimbert ◽  
Jerome Frappier ◽  
Jeanine Bedrossian ◽  
Christophe Legendre ◽  
Corinne Antoine ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Kidney Transplantation ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome

Membranous Nephropathy in Systemic Lupus Erythematosus: Long-Term Outcome and Prognostic Factors of 103 Patients

2012 ◽  
Vol 41 (5) ◽  
pp. 642-651 ◽  
Author(s):  
Gabriella Moroni ◽  
Silvana Quaglini ◽  
Luciana Gravellone ◽  
Beniamina Gallelli ◽  
Antonio Leoni ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Prognostic Factors ◽  
Lupus Erythematosus ◽  
Membranous Nephropathy ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome

Clinical characteristics and long-term outcomes of Libman–Sacks endocarditis in patients with systemic lupus erythematosus

Lupus ◽  
2020 ◽  
Vol 29 (9) ◽  
pp. 1115-1120 ◽  
Author(s):  
Byung-Woo Yoo ◽  
Sang-Won Lee ◽  
Jason Jungsik Song ◽  
Yong-Beom Park ◽  
Seung Min Jung
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Inflammatory Marker ◽  
Anticoagulation Therapy ◽  
Antiphospholipid Antibody ◽  
Systemic Lupus ◽  
Term Outcome ◽  
Long Term Outcome

Objective Treatment of Libman–Sacks (LS) endocarditis in patients with systemic lupus erythematosus (SLE) is challenging due to the lack of data. This study aimed to identify the clinical characteristics of SLE patients and LS endocarditis, and to investigate the treatment and prognosis of LS endocarditis. Methods Of all the patients with SLE who underwent echocardiography between 2010 and 2019, 11 and 29 patients with and without LS endocarditis, respectively, were included. We compared the inflammatory and thrombotic profiles between patients with and without LS endocarditis, and investigated the treatment and long-term outcome of LS endocarditis. Results No significant differences were observed in disease activity, clinical characteristics and inflammatory marker levels between patients with and without LS endocarditis. Patients with LS endocarditis had a significantly higher prevalence of antiphospholipid antibody (aPL) but a lower prevalence of SLE-specific antibody. Triple positivity of aPL was found in 72.7% and 13.8% of patients with and without LS endocarditis, respectively. Of 11 patients with LS endocarditis, six patients received anticoagulation therapy, and five patients received augmented immunosuppressive therapies. One patient who did not receive anticoagulation therapy developed cerebral infarction. Nine (82%) patients with LS endocarditis were classified as having antiphospholipid syndrome (APS). Despite the residual vegetation and valve dysfunction, surgical intervention was not required during the follow-up period of 56.8 months. Conclusion A significant correlation was observed between APS and LS endocarditis. Anticoagulation therapy should be considered to prevent thromboembolic complications in SLE patients with LS endocarditis.

Sign in / Sign up

Export Citation Format

Share Document